Evidence map›Paper›PMID 31016232›Full record

ArticleNPJ breast cancer2019

Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.

Ella F Jones, Kimberly M Ray, Wen Li, Amy J Chien, Rita A Mukhtar, Laura J Esserman, Benjamin L Franc, Youngho Seo, Miguel H Pampaloni, Bonnie N Joe and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Examining the evolving utility ofTranslational cancer research · 2020
    Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ella F Jones1Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA USA.
Kimberly M Ray1Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA USA.
Wen Li1Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA USA.
Amy J Chien2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA USA.
Rita A Mukhtar3Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA USA.
Laura J Esserman3Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA USA.
Benjamin L Franc1Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA USA.
Youngho Seo1Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA USA.
Miguel H Pampaloni1Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA USA.
Bonnie N Joe1Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA USA.
Nola M Hylton1Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA USA.
University of California, San Francisco · USUCSF Helen Diller Family Comprehensive Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dedicated breast positron emission tomography (dbPET) is an emerging technology with high sensitivity and spatial resolution that enables detection of sub-centimeter lesions and depiction of intratumoral heterogeneity. In this study, we report our initial experience with dbPET using [F-18]fluoroestradiol (FES) in assessing ER+ primary breast cancers. Six patients with >90% ER+ and HER2- breast cancers were imaged with dbPET and breast MRI. Two patients had ILC, three had IDC, and one had an unknown primary tumor. One ILC patient was treated with letrozole, and another patient with IDC was treated with neoadjuvant chemotherapy without endocrine treatment. In this small cohort, we observed FES uptake in ER+ primary breast tumors with specificity to ER demonstrated in a case with tamoxifen blockade. FES uptake in ILC had a diffused pattern compared to the distinct circumscribed pattern in IDC. In evaluating treatment response, the reduction of SUV

Identifiers

PMID31016232
PMCPMC6467896
OpenAlexW2938067365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.